Search results for abx831274

Pinatuzumab, Abbexa, abx831274

Pinatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD22, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Pinatuzumab vedotin is under investigation in clinical trial NCT01691898, A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).